Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative study

Folschweiller, Nicolas; Teixeira, Julio; Joshi, Smita; Goldani, Luciano Z.; Supparatpinyo, Khuanchai; Basu, Partha; Chotpitayasunondh, Tawee; Chetchotisakd, Ploenchan; Ruxrungtham, Kiat; Roteli-Martins, Cecilia; Grinsztejn, Beatriz; Quintana, Silvana Maria; Kumarasamy, Nagalingeswaran; Poongulali, Selvamuthu; Kulkarni, Vinay; Lin, Lan; Datta, Sanjoy K.; Descamps, Dominique; Dodet, Monique; Dubin, Gary; Friel, Damien; Hezareh, Marjan; Karkada, Naveen; Meric Camilleri, Dorothee; Poncelet, Sylviane; Salaun, Bruno; Tavares-da-Silva, Fernanda; Thomas-Jooris, Florence; Struyf, Frank.
Artículo en Inglés | ARCA | ID: arc-42413

Documentos relacionados

  1. AIDS Malignancy Consortium 054: Safety and Immunogenicity of the Quadrivalent Vaccine in Indian Women Living With HIV.
  2. Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative study.
  3. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
  4. Reading times of sentences with inclusive language in Spanish: a psycholinguistic study
  5. Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.
  6. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
  7. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
  8. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
  9. Protective and Harmful Immunity to RSV Infection.
  10. Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine.